First trimester combined screening – focus on early biochemistry

References

• Penrose L. A clinical and genetic study of 1280 cases of mental defects. Eugen Rev 1938;30:208–9.
   Google Scholar
• Penrose L. The relative effects of paternal and maternal age in mongolisn. J Genet 1933;27:219–24.
   Google Scholar
• Saugmann-Jensen P. Fosterdiagnostik og risikovurdering-rapport fra en arbejdsgruppe. [Prenatal dosgnostics and risk assessment - report from an expert group]. Danish Health Authority; 2003.
   Google Scholar
• Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:886–94.
   PubMed Web of Science ®Google Scholar
• Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984;1:926–9.
   PubMed Web of Science ®Google Scholar
• Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623–30.
   PubMed Web of Science ®Google Scholar
• Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome. Br J Obstet Gynaecol 1988;95:330–3.
   PubMedGoogle Scholar
• Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick JA. Maternal serum screening for Down’s syndrome in early pregnancy. Bmj 1988;297:883–7.
   PubMed Web of Science ®Google Scholar
• Van Lith JM, Pratt JJ, Beekhuis JR, Mantingh A. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down’s syndrome. Prenat Diagn 1992;12:801–6.
   PubMed Web of Science ®Google Scholar
• Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down’s syndrome. Ann Clin Biochem 1993;30:219–20.
   PubMed Web of Science ®Google Scholar
• Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down’s syndrome using maternal serum dimeric inhibin A. J Med Screen 1998;5:115–19.
   PubMed Web of Science ®Google Scholar
• Ozturk M, Bellet D, Manil L, Hennen G, Frydman R, Wands J. Physiological studies of human chorionic gonadotropin (hCG), alpha hCG, and beta hCG as measured by specific monoclonal immunoradiometric assays. Endocrinology 1987;120:549–58.
   PubMed Web of Science ®Google Scholar
• Ozturk M, Berkowitz R, Goldstein D, Bellet D, Wands JR. Differential production of human chorionic gonadotropin and free subunits in gestational trophoblastic disease. Am J Obstet Gynecol 1988;158:193–8.
   PubMed Web of Science ®Google Scholar
• Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, Romero K, Larsen JW Jr. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990;163:1248–53.
   PubMed Web of Science ®Google Scholar
• Spencer K. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down’s syndrome. Clin Chem 1991;37:809–14.
   PubMed Web of Science ®Google Scholar
• Ozturk M, Milunsky A, Brambati B, Sachs ES, Miller SL, Wands JR. Abnormal maternal serum levels of human chorionic gonadotropin free subunits in trisomy 18. Am J Med Genet 1990;36:480–3.
   PubMed Web of Science ®Google Scholar
• Macri JN, Spencer K, Aitken D, Garver K, Buchanan PD, Muller F, Boue A. First-trimester free beta (hCG) screening for Down syndrome. Prenat Diagn 1993;13:557–62.
   PubMed Web of Science ®Google Scholar
• Spencer K, Macri JN. Early detection of Down’s syndrome using free beta human choriogonadotropin. Ann Clin Biochem 1992;29:349–50.
   PubMed Web of Science ®Google Scholar
• Brock DJ, Barron L, Holloway S, Liston WA, Hillier SG, Seppala M. First-trimester maternal serum biochemical indicators in Down syndrome. Prenat Diagn 1990;10:245–51.
   PubMed Web of Science ®Google Scholar
• Cuckle HS, Wald NJ, Barkai G, Fuhrmann W, Altland K, Brambati B, Knight G, Palomaki G, Haddow JE, Canick J. First-trimester biochemical screening for Down syndrome. Lancet 1988;2:851–2.
   PubMed Web of Science ®Google Scholar
• Evans MI, Krantz DA, Hallahan TW, Galen RS. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. Am J Obstet Gynecol 2007;196:198–205.
   PubMed Web of Science ®Google Scholar
• Lin TM, Halbert SP, Kiefer D, Spellacy WN, Gall S. Characterization of four human pregnancy-associated plasma proteins. Am J Obstet Gynecol 1974;118:223–36.
   PubMed Web of Science ®Google Scholar
• Brambati B, Lanzani A, Tului L. Ultrasound and bioehemical assessment of first trimester pregnancy. In: Chapman MG, editor. The Embryo. London, UK: Springer Verlag; 1991. pp. 181–94.
   Google Scholar
• Muller F, Cuckle H, Teisner B, Grudzinskas JG. Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy. Prenat Diagn 1993;13:633–6.
   PubMed Web of Science ®Google Scholar
• Wald N, Stone R, Cuckle HS, Grudzinskas JG, Barkai G, Brambati B, Teisner B, Fuhrmann W. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down’s syndrome. BMJ 1992;305:28
   PubMed Web of Science ®Google Scholar
• Brambati B, Macintosh MC, Teisner B, Maguiness S, Shrimanker K, Lanzani A, Bonacchi I, Tului L, Chard T, Grudzinskas JG. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 1993;100:324–6.
   PubMedGoogle Scholar
• Brambati B, Tului L, Bonacchi I, Shrimanker K, Suzuki Y, Grudzinskas JG. Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome. Prenat Diagn 1994;14:1043–7.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Kennard A, Hackshaw AK. First trimester serum screening for Down’s syndrome. Prenat Diagn 1995;15:1227–40.
   PubMed Web of Science ®Google Scholar
• Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Down’s syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Br J Obstet Gynaecol 1996;103:407–12.
   PubMedGoogle Scholar
• Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867–9.
   PubMed Web of Science ®Google Scholar
• Pandya PP, Kondylios A, Hilbert L, Snijders RJ, Nicolaides KH. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 1995;5:15–19.
   PubMed Web of Science ®Google Scholar
• Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343–6.
   PubMed Web of Science ®Google Scholar
• Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376–83.
   PubMed Web of Science ®Google Scholar
• Noble PL, Abraha HD, Snijders RJ, Sherwood R, Nicolaides KH. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness. Ultrasound Obstet Gynecol 1995;6:390–5.
   PubMed Web of Science ®Google Scholar
• Tul N, Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn 1999;19:1035–42.
   PubMed Web of Science ®Google Scholar
• Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231–7.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down’s syndrome. Prenat Diagn 1997;17:821–9.
   PubMed Web of Science ®Google Scholar
• Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: a prospective study of 15,030 pregnancies. Ultrasound Obstet Gynecol 2002;20:219–25.
   PubMed Web of Science ®Google Scholar
• Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D’alton ME. First Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 2005;353:2001–11.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. Semin Perinatol 2005;29:225–35.
   PubMed Web of Science ®Google Scholar
• Cuckle HS, van Lith JM. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999;19:505–12.
   PubMed Web of Science ®Google Scholar
• Lin TM, Halbert SP, Spellacy WN. Measurement of pregnancy-associated plasma proteins during human gestation. J Clin Invest 1974;54:576–82.
   PubMed Web of Science ®Google Scholar
• Folkersen J, Grudzinskas JG, Hindersson P, Teisner B, Westergaard JG. Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. Am J Obstet Gynecol 1981;139:910–4.
   PubMed Web of Science ®Google Scholar
• Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 1993;268:12243–6.
   PubMed Web of Science ®Google Scholar
• Oxvig C, Sand O, Kristensen T, Kristensen L, Sottrup-Jensen L. Isolation and characterization of circulating complex between human pregnancy-associated plasma protein-A and proform of eosinophil major basic protein. Biochim Biophys Acta 1994;1201:415–23.
   PubMed Web of Science ®Google Scholar
• Overgaard MT, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M, Gleich GJ, Sottrup-Jensen L, Conover CA, Oxvig C. Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J Biol Chem 2000;275:31128–33.
   PubMed Web of Science ®Google Scholar
• Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR 3rd, Conover CA. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999;96:3149–53.
   PubMed Web of Science ®Google Scholar
• Laursen LS, Overgaard MT, Soe R, Boldt HB, Sottrup-Jensen L, Giudice LC, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 2001;504:36–40.
   PubMed Web of Science ®Google Scholar
• Giudice LC, Conover CA, Bale L, Faessen GH, Ilg K, Sun I, Imani B, Suen LF, Irwin JC, Christiansen M, Overgaard MT, Oxvig C. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab 2002;87:2359–66.
   PubMed Web of Science ®Google Scholar
• Guibourdenche J, Frendo JL, Pidoux G, Bertin G, Luton D, Muller F, Porquet D, Evain-Brion D. Expression of pregnancy-associated plasma protein-A (PAPP-A) during human villous trophoblast differentiation in vitro. Placenta 2003;24:532–9.
   PubMed Web of Science ®Google Scholar
• Han VK, Bassett N, Walton J, Challis JR. The expression of insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. J Clin Endocrinol Metab 1996;81:2680–93.
   PubMed Web of Science ®Google Scholar
• Sun IY, Overgaard MT, Oxvig C, Giudice LC. Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane. J Clin Endocrinol Metab 2002;87:5235–40.
   PubMed Web of Science ®Google Scholar
• Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 1990;71:797–805.
   PubMed Web of Science ®Google Scholar
• Rizzo G, Silvestri E, Capponi A, Servadei F, Pietrolucci ME, Capece A, Pisa R, Arduini D. Histomorphometric characteristics of first trimester chorionic villi in pregnancies with low serum pregnancy-associated plasma protein-A levels: relationship with placental three-dimensional power doppler ultrasonographic vascularization. J Matern Fetal Neonatal Med 2011;24:253–7.
   PubMed Web of Science ®Google Scholar
• Prefumo F, Canini S, Crovo A, Pastorino D, Venturini PL, De Biasio P. Correlation between first trimester fetal bone length and maternal serum pregnancy-associated plasma protein-A (PAPP-A). Hum Reprod 2006;21:3019–21.
   PubMed Web of Science ®Google Scholar
• Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner R, First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004;191:1452–8.
   PubMed Web of Science ®Google Scholar
• Barrett SL, Bower C, Hadlow NC. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diagn 2008;28:28–35.
   PubMed Web of Science ®Google Scholar
• Hay DL. Placental histology and the production of human choriogonadotrophin and its subunits in pregnancy. Br J Obstet Gynaecol 1988;95:1268–75.
   PubMedGoogle Scholar
• Frendo JL, Vidaud M, Guibourdenche J, Luton D, Muller F, Bellet D, Giovagrandi Y, Tarrade A, Porquet D, Blot P, Evain-Brion D. Defect of villous cytotrophoblast differentiation into syncytiotrophoblast in Down’s syndrome. J Clin Endocrinol Metab 2000;85:3700–7.
   PubMed Web of Science ®Google Scholar
• Oktay K, Brzyski RG, Miller EB, Krugman D. Association of serum beta-hCG levels with myosalpingeal invasion and viable trophoblast mass in tubal pregnancy. Obstet Gynecol 1994;84:803–6.
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Hochberg A, deGroot N, Weinstein D. High maternal serum chorionic gonadotropin level in Down’s syndrome pregnancies is caused by elevation of both subunits messenger ribonucleic acid level in trophoblasts. J Clin Endocrinol Metab 1995;80:3528–31.
   PubMed Web of Science ®Google Scholar
• Massin N, Frendo JL, Guibourdenche J, Luton D, Giovangrandi Y, Muller F, Vidaud M, Evain-Brion D. Defect of syncytiotrophoblast formation and human chorionic gonadotropin expression in Down’s syndrome. Placenta 2001;22:S93–7.
   PubMed Web of Science ®Google Scholar
• Roberts L, Sebire NJ, Fowler D, Nicolaides KH. Histomorphological features of chorionic villi at 10–14 weeks of gestation in trisomic and chromosomally normal pregnancies. Placenta 2000;21:678–83.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Uldbjerg N, Vereecken A, Tørring N. First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised? Prenat Diagn 2008;28:1156–9.
   PubMed Web of Science ®Google Scholar
• Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002;39:567–76.
   PubMed Web of Science ®Google Scholar
• Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down’s syndrome associated pregnancy. Ann Clin Biochem 1990;27:452–8.
   PubMed Web of Science ®Google Scholar
• Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down’s syndrome. J Med Screen 2002;9:2–6.
   PubMed Web of Science ®Google Scholar
• Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142–5.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493–502.
   PubMed Web of Science ®Google Scholar
• de Graaf IM, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, van Lith JM. Co-variables in first trimester maternal serum screening. Prenat Diagn 2000;20:186–9.
   PubMed Web of Science ®Google Scholar
• Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 2003;23:851–5.
   PubMed Web of Science ®Google Scholar
• Spencer K, Ong CY, Liao AW, Nicolaides KH. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 2000;20:491–4.
   PubMed Web of Science ®Google Scholar
• Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn 2005;25:365–9.
   PubMed Web of Science ®Google Scholar
• Ball S, Ekelund C, Wright D, Kirkegaard I, Norgaard P, Petersen OB, Tabor A, Danish Fetal Medicine Study Group. Temporal effects of maternal and pregnancy characteristics on serum pregnancy-associated plasma protein-A and free beta-human chorionic gonadotropin at 7–14 weeks’ gestation. Ultrasound Obstet Gynecol 2013;41:33–9.
   PubMed Web of Science ®Google Scholar
• Spencer K, Bindra R, Cacho AM, Nicolaides KH. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 2004;24:169–73.
   PubMed Web of Science ®Google Scholar
• Metzenbauer M, Hafner E, Hoefinger D, Schuchter K, Stangl G, Ogris E, Philipp K. Three-dimensional ultrasound measurement of the placental volume in early pregnancy: method and correlation with biochemical placenta parameters. Placenta 2001;22:602–5.
   PubMed Web of Science ®Google Scholar
• Burton GJ, Palmer ME, Dalton KJ. Morphometric differences between the placental vasculature of non-smokers, smokers and ex-smokers. Br J Obstet Gynaecol 1989;96:907–15.
   PubMedGoogle Scholar
• Larsen LG, Clausen HV, Jonsson L. Stereologic examination of placentas from mothers who smoke during pregnancy. Am J Obstet Gynecol 2002;186:531–7.
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Burton GJ. The effect of smoking in pregnancy on early placental morphology. Obstet Gynecol 1992;79:645–8.
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Suri S, Muttukrishna S. Evaluation of the impact of maternal smoking on ultrasound and endocrinological markers of first trimester placentation. Early Hum Dev 2013;89:777–80.
   PubMed Web of Science ®Google Scholar
• van Oppenraaij RH, Koning AH, van den Hoff MJ, van der Spek PJ, Steegers EA, Exalto N. The effect of smoking on early chorionic villous vascularisation. Placenta 2012;33:645–51.
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Burton GJ. Morphological and biological effects of maternal exposure to tobacco smoke on the feto-placental unit. Early Hum Dev 2007;83:699–706.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Spencer CE, Achillea N. A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn 2010;30:937–40.
   PubMed Web of Science ®Google Scholar
• Madsen HN, Ekelund CK, Tørring N, Ovesen PG, Friis-Hansen L, Ringholm L, Petersen OB. Impact of type 1 diabetes and glycemic control on fetal aneuploidy biochemical markers. Acta Obstet Gynecol Scand 2012;91:57–61.
   PubMed Web of Science ®Google Scholar
• Pellitero S, Reverter JL, Pizarro E, Pastor MC, Granada ML, Tassies D, Reverter JC, Salinas I, Sanmarti A. Pregnancy-associated plasma protein-a levels are related to glycemic control but not to lipid profile or hemostatic parameters in type 2 diabetes. Diabetes Care 2007;30:3083–5.
   PubMed Web of Science ®Google Scholar
• Resch ZT, Chen BK, Bale LK, Oxvig C, Overgaard MT, Conover CA. Pregnancy-associated plasma protein a gene expression as a target of inflammatory cytokines. Endocrinology 2004;145:1124–9.
   PubMed Web of Science ®Google Scholar
• Gjerris AC, Tabor A, Loft A, Christiansen M, Pinborg A. First trimester prenatal screening among women pregnant after IVF/ICSI. Hum Reprod Update 2012;18:350–9.
   PubMed Web of Science ®Google Scholar
• Gjerris AC, Loft A, Pinborg A, Christiansen M, Tabor A. First-trimester screening markers are altered in pregnancies conceived after IVF/ICSI. Ultrasound Obstet Gynecol 2009;33:8–17.
   PubMed Web of Science ®Google Scholar
• Amor DJ, Xu JX, Halliday JL, Francis I, Healy DL, Breheny S, Baker HW, Jaques AM. Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome. Hum Reprod 2009;24:1330–8.
   PubMed Web of Science ®Google Scholar
• Engels MA, Kooij M, Schats R, Twisk JW, Blankenstein MA, van Vugt JM. First-trimester serum marker distribution in singleton pregnancies conceived with assisted reproduction. Prenat Diagn 2010;30:372–7.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ. Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers. Prenat Diagn 2013;33:124–9.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cuckle HS. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates? Prenat Diagn 2002;22:903–6.
   PubMed Web of Science ®Google Scholar
• Norgaard P, Wright D, Ball S, Newell P, Kirkegaard I, Petersen OB, Uldbjerg N, Tørring N, Jorgensen FS, Friis-Hansen L, Ekelund C, Tabor A, Sorensen S. Autocorrelation and cross-correlation between hCGbeta and PAPP-A in repeated sampling during first trimester of pregnancy. Clin Chem Lab Med 2013;51:1781–8.
   PubMed Web of Science ®Google Scholar
• Spencer K. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies. Prenat Diagn 2001;21:445–7.
   PubMed Web of Science ®Google Scholar
• Spencer K. Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited. Prenat Diagn 2002;22:874–6.
   PubMed Web of Science ®Google Scholar
• Wright D, Syngelaki A, Birdir C, Bedei I, Nicolaides KH. First-trimester screening for trisomy 21 with adjustment for biochemical results of previous pregnancies. Fetal Diagn Ther 2011;30:194–202.
   PubMed Web of Science ®Google Scholar
• Laigaard J, Sorensen T, Frohlich C, Pedersen BN, Christiansen M, Schiott K, Uldbjerg N, Albrechtsen R, Clausen HV, Ottesen B, Wewer UM. ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 2003;23:1086–91.
   PubMed Web of Science ®Google Scholar
• Laigaard J, Christiansen M, Frohlich C, Pedersen BN, Ottesen B, Wewer UM. The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn 2005;25:45–6.
   PubMed Web of Science ®Google Scholar
• Laigaard J, Cuckle H, Wewer UM, Christiansen M. Maternal serum ADAM12 levels in Down and Edwards’ syndrome pregnancies at 9–12 weeks’ gestation. Prenat Diagn 2006;26:689–91.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Stamatopoulou A. Maternal serum ADAM12s in the late first trimester of pregnancies with trisomy 21. Prenat Diagn 2008;28:422–4.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Uldbjerg N, Tørring N. First-trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled? Prenat Diagn 2008;28:338–42.
   PubMed Web of Science ®Google Scholar
• Wortelboer EJ, Linskens IH, Koster MP, Stoutenbeek P, Cuckle H, Blankenstein MA, Visser GH, van Vugt JM, Schielen PC. ADAM12s as a first-trimester screening marker of trisomy. Prenat Diagn 2009;29:866–9.
   PubMed Web of Science ®Google Scholar
• Tørring N, Ball S, Wright D, Sarkissian G, Guitton M, Darbouret B. First trimester screening for trisomy 21 in gestational week 8–10 by ADAM12-S as a maternal serum marker. Reprod Biol Endocrinol 2010;8:129–7827-8-129.
   PubMed Web of Science ®Google Scholar
• Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH. Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11–13 weeks. Am J Obstet Gynecol 2009;200:508.e1–e6.
   PubMed Web of Science ®Google Scholar
• Valinen Y, Marttala J, Sahravand M, Jarvela I, Honkasalo T, Laitinen P, Ryynanen M. Adding ADAM12 in risk calculation program does not improve the detection rate of trisomies 18 and 13 in first trimester screening. J Matern Fetal Neonatal Med 2012;25:822–5.
   PubMed Web of Science ®Google Scholar
• Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, Vatish M, Wertaschnigg D, Galindo A. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241–6.
   PubMed Web of Science ®Google Scholar
• Huang T, Dennis A, Meschino WS, Rashid S, Mak-Tam E, Cuckle H. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-beta human chorionic gonadotrophin, placental growth factor, and alpha-fetoprotein. Prenat Diagn 2015;35:709–16.
   PubMed Web of Science ®Google Scholar
• Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH. Maternal serum placental growth factor in prospective screening for aneuploidies at 8–13 weeks’ gestation. Fetal Diagn Ther 2012;31:87–93.
   PubMed Web of Science ®Google Scholar
• Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013;42:41–50.
   PubMed Web of Science ®Google Scholar
• Cowans NJ, Stamatopoulou A, Tørring N, Spencer K. Early first-trimester maternal serum placental growth factor in trisomy 21 pregnancies. Ultrasound Obstet Gynecol 2011;37:515–19.
   PubMed Web of Science ®Google Scholar
• Koster MP, Wortelboer EJ, Stoutenbeek P, Visser GH, Schielen PC. Modeling Down syndrome screening performance using first-trimester serum markers. Ultrasound Obstet Gynecol 2011;38:134–9.
   PubMed Web of Science ®Google Scholar
• Cowans NJ, Alfthan H, Stenman UH, Spencer K. Stability of first trimester placental growth factor in serum and whole blood. Prenat Diagn 2011;31:1193–7.
   PubMed Web of Science ®Google Scholar
• Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down’s syndrome. Ann Clin Biochem 2003;40:219–31.
   PubMed Web of Science ®Google Scholar
• Alldred SK, Takwoingi Y, Guo B, Pennant M, Deeks JJ, Neilson JP, Alfirevic Z. First trimester serum tests for Down’s syndrome screening. Cochrane Database Syst Rev 2015;11:CD011975.
   PubMed Web of Science ®Google Scholar
• Kirkegaard I, Petersen OB, Uldbjerg N, Tørring N. Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks. Prenat Diagn 2008;28:839–44.
   PubMed Web of Science ®Google Scholar
• Tørring N, Petersen OB, Uldbjerg N. Ten years of experience with first-trimester screening for fetal aneuploidy employing biochemistry from gestational weeks 6 + 0 to 13 + 6. Fetal Diagn Ther 2015;37:51–7.
   PubMed Web of Science ®Google Scholar
• Wright D, Spencer K, Kagan KK, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH. First-trimester combined screening for trisomy 21 at 7–14 weeks’ gestation. Ultrasound Obstet Gynecol 2010;36:404–11.
   PubMed Web of Science ®Google Scholar
• Madsen HN, Petersen OB, Tørring N. Screening for fetal trisomy 21 in gestational weeks 6 and 7. Acta Obstet Gynecol Scand 2010;89:1218–21.
   PubMed Web of Science ®Google Scholar
• Kuc S, Koster MP, Visser GH, Schielen PC. Performance of first-trimester serum screening for trisomy 21 before and from 11 + 0 weeks of gestational age in The Netherlands. Prenat Diagn 2010;30:906–8.
   PubMed Web of Science ®Google Scholar
• Engels MA, Twisk JW, Blankenstein MA, van Vugt JM. First-trimester screening for Down syndrome with serum sampling at different gestational ages: the effect on screening performance. Fetal Diagn Ther 2014;36:293–8.
   PubMed Web of Science ®Google Scholar
• Tørring N. Performance of first-trimester screening between gestational weeks 7 and 13. Clin Chem 2009;55:1564–7.
   PubMed Web of Science ®Google Scholar
• Ekelund C, Wright D, Ball S, Kirkegaard I, Norgaard P, Sorensen S, Friis-Hansen L, Jorgensen FS, Tørring N, Bech BH, Petersen OB, Tabor A. Prospective study evaluating performance of first-trimester combined screening for trisomy 21 using repeat sampling of maternal serum markers PAPP-A and free beta-hCG. Ultrasound Obstet Gynecol 2012;40:276–81.
   PubMed Web of Science ®Google Scholar
• Spencer K, Kagan KO, Nicolaides KH. Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 2008;28:49–52.
   PubMed Web of Science ®Google Scholar
• Linskens IH, Spreeuwenberg MD, Blankenstein MA, van Vugt JM. Early first-trimester free beta-hCG and PAPP-A serum distributions in monochorionic and dichorionic twins. Prenat Diagn 2009;29:74–8.
   PubMed Web of Science ®Google Scholar
• Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 2000;20:91–5.
   PubMed Web of Science ®Google Scholar
• Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years’ experience. Bjog 2003;110:276–80.
   PubMed Web of Science ®Google Scholar
• Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K. A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester. Ultrasound Obstet Gynecol 2011;37:38–47.
   PubMed Web of Science ®Google Scholar
• Prats P, Rodriguez I, Comas C, Puerto B. Systematic review of screening for trisomy 21 in twin pregnancies in first trimester combining nuchal translucency and biochemical markers: a meta-analysis. Prenat Diagn 2014;34:1077–83.
   PubMed Web of Science ®Google Scholar
• Yaron Y, Ochshorn Y, Tsabari S, Shira AB. First-trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A can detect triploidy and determine the parental origin. Prenat Diagn 2004;24:445–50.
   PubMed Web of Science ®Google Scholar
• Petersen OB, Vogel I, Ekelund C, Hyett J, Tabor A, Danish Fetal Medicine Study Group, Danish Clinical Genetics Study Group. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. Ultrasound Obstet Gynecol 2014;43:265–71.
   PubMed Web of Science ®Google Scholar
• Alamillo CM, Krantz D, Evans M, Fiddler M, Pergament E. Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center. Prenat Diagn 2013;33:251–6.
   PubMed Web of Science ®Google Scholar
• Engelbrechtsen L, Brondum-Nielsen K, Ekelund C, Tabor A, Skibsted L, Danish Fetal Medicine Study Group. Detection of triploidy at 11–14 weeks’ gestation: a cohort study of 198,000 pregnant women. Ultrasound Obstet Gynecol 2013;42:530.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Anderson JM, Anwandter G, Neksasova K, Nicolaides KH. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation. Prenat Diagn 2008;28:1209–13.
   PubMed Web of Science ®Google Scholar
• Spencer K, Pertile MD, Bonacquisto L, Mills I, Turner S, Donalson K, Jonsson JJ. First trimester detection of trisomy 16 using combined biochemical and ultrasound screening. Prenat Diagn 2014;34:291–5.
   PubMed Web of Science ®Google Scholar
• Tørring N, Petersen OB, Becher N, Vogel I, Uldbjerg N, Danish Fetal Medicine Study Group, Danish Clinical Genetics Study Group. First trimester screening for other trisomies than trisomy 21, 18, and 13. Prenat Diagn 2015;35:612–19.
   PubMed Web of Science ®Google Scholar
• Neiswanger K, Hohler PM, Hively-Thomas LB, McPherson EW, Hogge WA, Surti U. Variable outcomes in mosaic trisomy 16: five case reports and literature analysis. Prenat Diagn 2006;26:454–61.
   PubMed Web of Science ®Google Scholar
• Rodriguez MJ, Moreno-Cid M, Rubio A, Pastor C, De Leon J, Puerto B, Garcia J, Rodriguez MM. Trisomy 8 mosaicism a controversial prenatal diagnosis. J Obstet Gynaecol 2013;33:204–5.
   PubMedGoogle Scholar
• Sepulveda W, Wimalasundera RC, Taylor MJ, Blunt S, Be C, De La Fuente S. Prenatal ultrasound findings in complete trisomy 9. Ultrasound Obstet Gynecol 2003;22:479–83.
   PubMed Web of Science ®Google Scholar
• Mavromatidis G, Dinas K, Delkos D, Vosnakis C, Mamopoulos A, Rousso D. Case of prenatally diagnosed non-mosaic trisomy 20 with minor abnormalities. J Obstet Gynaecol Res 2010;36:866–8.
   PubMed Web of Science ®Google Scholar
• Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015;45:249–66.
   PubMed Web of Science ®Google Scholar
• Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH. Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities. Fetal Diagn Ther 2014;35:174–84.
   PubMed Web of Science ®Google Scholar
• Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, Savage M, Platt LD, Saltzman D, Grobman WA, Klugman S, Scholl T, Simpson JL, McCall K, Aggarwal VS, Bunke B, Nahum O, Patel A, Lamb AN, Thom EA, Beaudet AL, Ledbetter DH, Shaffer LG, Jackson L. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012;367:2175–84.
   PubMed Web of Science ®Google Scholar
• Curnow KJ, Wilkins-Haug L, Ryan A, Kirkizlar E, Stosic M, Hall MP, Sigurjonsson S, Demko Z, Rabinowitz M, Gross SJ. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based non-invasive prenatal test. Am J Obstet Gynecol 2015;212:79.e1–e9.
   PubMed Web of Science ®Google Scholar
• Lo KK, Karampetsou E, Boustred C, McKay F, Mason S, Hill M, Plagnol V, Chitty LS. Limited clinical utility of non-invasive prenatal testing for subchromosomal abnormalities. Am J Hum Genet 2016;98:34–44.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Schmid M, Hoopmann M, Wagner P, Abele H. Screening performance and costs of different strategies in prenatal screening for trisomy 21. Geburtshilfe Frauenheilkd 2015;75:244–50.
   PubMed Web of Science ®Google Scholar
• Biagiotti R, Cariati E, Brizzi L, Cappelli G, D’Agata A. Maternal serum screening for trisomy 18 in the first trimester of pregnancy. Prenat Diagn 1998;18:907–13.
   PubMed Web of Science ®Google Scholar